Skip to main content

Table 1 Prevalence of autoantibodies in Mexican patients with PM/DM

From: Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

  PM/DM PM DM Adult-onset DM Juvenile- onset DM
Number 95 29 66 61 5
Age 44.4 48.4 42.8 45.3 18.2
Mean ± SD ± 14.2 ± 10.2 ± 15.3 ± 14.4 ± 9.7
Male 33% 41% 29% 28% 40%
Autoantibodies      
   Jo-1 4% 7% 3% 3% 0%
Mi-2
(95% CI)
35% 10%a
(2.1 to 26.5)
45%a
(33.1 to 58.2)
45% 40%
p155/140
(95% CI)
11% 0%b
(0.0 to 11.9)
15%b
(7.5 to 26.1)
16% 0%
   MJ/NXP-2 3% 0% 5% 3% 20%
   SAE 2% 0% 3% 3% 0%
   SRP 3% 7% 2% 2% 0%
   PM-Scl 3% 0% 5% 5% 0%
   U1RNP 3% 7% 2% 2% 0%
   Negative 36% 69%c 21%c 20% 40%
   Su/Ago2 8% 7% 9% 10% 0%
   Ro60 13% 7% 15% 15% 20%
   Ro52d 21% 16% 22% 24% 0%
  1. aP < 0.0001; bP < 0.05; cP < 0.0001 by Fisher exact test; dsome samples were not tested due to availability. All were determined by immunoprecipitation except anti-Ro52 determined by ELISA. Anti-EJ, PL-7, PL-12, OJ were not found. DM, dermatomyositis; negative, negative for myositis-specifc/related autoantibodies, anti-Jo-1 to -U1RNP in the table; PM, polymyositis; SAE, small ubiquitin-like modifier activating enzyme; SRP, signal recognition particle.